Hematologic effects of linezolid: summary of clinical experience
- PMID: 12121967
- PMCID: PMC127358
- DOI: 10.1128/AAC.46.8.2723-2726.2002
Hematologic effects of linezolid: summary of clinical experience
Abstract
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.
Figures
References
-
- Adult AIDS Clinical Trial Group (AACTG). 1992. Table for grading severity of adult adverse experiences. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md.
-
- Alanis, A., and A. J. Weinstein. 1983. Adverse reactions associated with the use of oral penicillins and cephalosporins. Med. Clin. N. Am. 67:113-129. - PubMed
-
- Beris, P., and P. A. Miescher. 1988. Hematological complications of antiinfectious agents. Sem. Hematol. 25:123-139. - PubMed
-
- Brickner, S. J., D. K. Hutchinson, M. R. Barbachyn, R. R. Mannienen, D. A. Ulanowicz, K. C. Grega, S. K. Hendes, D. S. Toops, C. W. Ford, and G. E. Zurenko. 1996. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 39:673-679. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
